Olema Pharmaceuticals (OLMA) Depreciation & Amortization (CF) (2020 - 2026)
Olema Pharmaceuticals (OLMA) reported Depreciation & Amortization (CF) of $119000.0 for Q1 2026, down 7.03% year-over-year from $128000.0 in Q1 2025, and down 36.36% quarter-over-quarter from $187000.0 in Q4 2025.
Olema Pharmaceuticals (OLMA) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $119000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $119000.0, down 7.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $481000.0 (up 11.09% YoY), and the FY2025 annual result was $490000.0, up 24.68% from the prior year.
- Depreciation & Amortization (CF) declined to $119000.0 in Q1 2026 per OLMA's latest filing, from $187000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $187000.0 in Q4 2025 and troughed at $43000.0 in Q3 2025.
- A 5-year average of $102117.6 and a median of $95000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) soared 833.33% in 2022, then sank 54.74% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $97000.0 in 2022, then slipped by 9.28% to $88000.0 in 2023, then surged by 31.82% to $116000.0 in 2024, then jumped by 61.21% to $187000.0 in 2025, then plunged by 36.36% to $119000.0 in 2026.
- Business Quant data shows OLMA's Depreciation & Amortization (CF) at $119000.0 in Q1 2026, $187000.0 in Q4 2025, and $43000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 429,663.65 |
| 10 | Olema Pharmaceuticals | 1.01 Bn | 1.01 Bn | - | 119,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 119,000.00 |
| Mar 31, 2026 | 119,000.00 |
| Dec 31, 2025 | 187,000.00 |
| Dec 31, 2025 | 187,000.00 |
| Sep 30, 2025 | 43,000.00 |
| Sep 30, 2025 | 43,000.00 |
| Jun 30, 2025 | 132,000.00 |
| Jun 30, 2025 | 132,000.00 |
| Mar 31, 2025 | 128,000.00 |
| Mar 31, 2025 | 128,000.00 |
| Dec 31, 2024 | 116,000.00 |
| Dec 31, 2024 | 116,000.00 |
| Sep 30, 2024 | 95,000.00 |
| Sep 30, 2024 | 95,000.00 |
| Jun 30, 2024 | 94,000.00 |
| Jun 30, 2024 | 94,000.00 |
| Mar 31, 2024 | 88,000.00 |
| Mar 31, 2024 | 88,000.00 |
| Dec 31, 2023 | 88,000.00 |
| Dec 31, 2023 | 88,000.00 |